Ganirelix is a synthetic decapeptide that functions as a gonadotropin-releasing hormone (GnRH) antagonist. It is primarily used in assisted reproductive technology to prevent premature ovulation during controlled ovarian stimulation. The structure of Ganirelix consists of a sequence of amino acids that inhibit the action of GnRH, thereby suppressing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. This action helps to control the timing of ovulation and improve the chances of successful fertilization. Ganirelix is typically administered via subcutaneous injection and is known for its relatively short half-life, necessitating careful timing in relation to fertility treatments. The compound is characterized by its stability and specificity in binding to GnRH receptors, making it an effective tool in reproductive medicine. As with any medication, potential side effects may include injection site reactions and hormonal imbalances, which should be monitored by healthcare professionals.

Ganirelix 1-4 peptide

208599-57-9: Ganirelix is a synthetic decapeptide that functions as a gonadotropin-releasing hormone (GnRH) antagonist. It is primarily used in assisted reproductive technology to prevent premature ovulation during controlled ovarian stimulation. The structure of Ganirelix consists of a sequence of amino acids that inhibit the action of GnRH, thereby suppressing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. This action helps to control the timing of ovulation and improve the chances of successful fertilization. Ganirelix is typically administered via subcutaneous injection and is known for its relatively short half-life, necessitating careful timing in relation to fertility treatments. The compound is characterized by its stability and specificity in binding to GnRH receptors, making it an effective tool in reproductive medicine. As with any medication, potential side effects may include injection site reactions and hormonal imbalances, which should be monitored by healthcare professionals.

CAS 208599-57-9

Ganirelix 1-4 peptide

Cetrorelix Impurity 22 Trifluoroacetate

Ref: 4Z-PC-252025

Ganirelix 1-4 Peptide

Ref: ST-EA-CP-G37009